Products
Bausch + Lomb reports statistically significant data on novel dry eye supplement
Randomized study suggests Blink NutriTears may restore tear film homeostasis by addressing DED’s key root causes.
Events
Bausch + Lomb and GRF launch glaucoma awareness campaign
Glaucoma Research Foundation partners on patient-targeted initiative to honor January as Glaucoma Awareness Month.
Products
FDA approves Bausch+ Lomb’s TENEO excimer laser platform
Now considered the smallest excimer laser by footprint in the U.S., it’s designed for LASIK surgery in patients with myopia and myopic astigmatism.
Products
Bausch + Lomb launches SeeNa ophthalmic diagnostic system
Optical biometry and topography system can integrate with the eyeTELLIGENCE platform.
Products
Bausch + Lomb launches new surgical planning software
Latest technology is designed for the cloud-based eyeTELLIGENCE platform.
Products
Bausch + Lomb launches enVista Aspire IOL in the US
New IOL addition to the enVista family treats lower levels of astigmatism with optimized extended range of vision.
Products
Bausch + Lomb officially acquires Xiidra from Novartis
The $2.5 billion-deal also includes two “front-of-eye” assets.
Products
Bausch + Lomb launches LUMIFY EYE ILLUMINATIONS
Three new hypoallergenic specialty eye care products target the sensitive eye area.
Products
Bausch + Lomb launches MIEBO in the US
Preservative-free eye drop is the first and only approved DED treatment that directly targets tear evaporation.
Business
Bausch + Lomb adds new executives to leadership team
Roles include two vice presidents and two newly-created positions.
Products
Bausch + Lomb buys Blink eye drops from Johnson & Johnson Vision
Eye and contact lens drops will expand the company’s over-the-counter products.
Products
Bausch + Lomb to acquire Xiidra from Novartis
Deal is worth up to $2.5 billion; includes AcuStream delivery technology and two investigational compounds for chronic ocular surface pain.
Products
Bausch + Lomb launches PreserVision AREDS 2 formula mini soft gels with CoQ10
Latest U.S. product rollout targets reducing the risk of moderate-to-severe AMD with heart health support.
Products
Bausch + Lomb launches Biotrue Hydration Boost CL rehydrating drops
The first and only preservative-free rehydrating drop in a multi-dose bottle is now available in the US.
Products
Bausch + Lomb launches INFUSE multifocal SiHy contact lenses in US
Daily disposable lenses target minimizing lens dryness for presbyopia patients.
Products
Bausch + Lomb and Novaliq receive FDA approval for MIEBO to treat DED
Formerly known as NOV03, the ophthalmic solution is now the first and only approved DED treatment directly targeting tear evaporation.
Products
Bausch + Lomb launches StableVisc OVD, TotalVisc Viscoelastic System in US
New options provide cataract surgeons with dual-action protection during procedure.
Pipeline
Bausch + Lomb, Novaliq release second phase 3 data for NOV03
Results from MOJAVE study support potential for treating DED associated with MGD.
Products
Bausch + Lomb receives FDA premarket approval for StableVisc OVD
Ophthalmic Viscoelastic Device to be injected via a syringe during cataract surgery to prevent tissue damage.
Business